newsfilter
← Latest News
GlobeNewswire·

Electra Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference in London

  • Electra Therapeutics (NASDAQ: ETRA) announced management will present at the Jefferies Global Healthcare Conference in London on Wednesday, November 18, 2026, at 1:00 p.m. GMT.
  • A live webcast of the presentation will be available in the Investors section of the company's website at ir.electra-therapeutics.com, with a replay accessible after the event.
  • The company is a late clinical-stage biopharmaceutical firm pioneering precision medicines targeting signal regulatory proteins (SIRP) for immune-mediated diseases & cancer.
  • Lead candidate ipsoprubart (ELA026), a novel pan-SIRP monoclonal antibody, is in a global registrational program for secondary hemophagocytic lymphohistiocytosis (sHLH).
  • Ipsoprubart is also under evaluation in a Phase 1 clinical trial for relapsed/refractory T-cell & natural-killer cell malignancies.
  • ELA822, the second clinical-stage candidate, is a novel SIRPγ-specific antibody being developed for chronic T cell-mediated immune & inflammatory diseases.
  • Investor inquiries should be directed to Renee Leck at THRUST (Renee@thrustsc.com), while media inquiries should contact Sarah Sutton at THRUST (sarah@thrustsc.com).